Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

i>

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. There can be no assurance that we will conduct additional studies with for acute treatment of HAE or that we will be successful in gaining regulatory approval of Cinryze for additional indications, formulations or in additional territories. In addition, approval of a competing product which has been granted orphan drug designation would prevent Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2008 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

                              VIROPHARMA INCORPORATED
                       Selected Financial Information- GAAP

    Consolidated Statements of Operations:
    (in thousands, except per           Three months ended   Six months ended
     share 
'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Pregnant women who live in leafy, green neighborhoods are less ... new study suggests. Researchers analyzed data from more than ... who lived in a neighborhood with plenty of trees, grass ... very preterm birth (before 30 weeks) and a 13 percent ... Babies born to mothers who lived in greener neighborhoods ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... patients burdened by stress and family conflicts before surgery ... operation, a new study suggests. Investigators found that ... a nearly three times greater risk for complications compared ... life. "We,ve long known that patient quality of ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, ... of the project’s social media efforts. StudioPMG is honored to ... the perception of beauty as it applies to disabled women. ... by Shelly Baer and Vanessa Silberman, who wanted to create ... beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen ...
(Date:9/19/2014)... to reducing poverty that help children and their ... and foundations. By combining education and training for ... that offer a path out of poverty with ... programs aim to improve the life opportunities of ... from the National Center for Children in Poverty ...
Breaking Medicine News(10 mins):Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2
... Jan. 31 (HealthDay News) -- Super Bowl fans, beware: ... and the Green Bay Packers could be a killer, ... withstand the emotional stress that comes with watching the ... risk appears real, a Los Angeles-based study team cautions, ...
... bacteria to build an extra natural layer of nanoparticle-like armour ... a startlingly simple way to give drug bearing polymer vesicles ... The Warwick researchers have been able to decorate ... new strategy in the design of vehicles for drug release, ...
... is a pathological syndrome that is usually classified into ... the Milwaukee criteria. However, this classification has some drawbacks ... classification and failure to properly guide diagnosis and treatment. ... in the World Journal of Gastroenterology addresses ...
... Oncology (ISCO) will collaborate to publish Cellular Oncology ... the official journal of ISCO and publishes original papers ... It was previously published by IOS Press. ... clinical disciplines involved in basic and translational cancer research ...
... , SATURDAY, Jan. 29 (HealthDay News) -- An ... decided on Friday that electroconvulsive (also known as "electroshock") ... as other medical devices entering the market. ... decades-old controversy surrounding the psychiatric treatment, which some patients ...
... Jan. 30 (HealthDay News) -- It may not be news to those ... reports that if you,re aboard a ship, looking at the horizon can ... investigators compared a group of crew members as they stood on land ... front of them and then a far-off object -- a distant mountain ...
Cached Medicine News:Health News:Super Bowl Loss Really a Heart Stopper for Some Fans 2Health News:Super Bowl Loss Really a Heart Stopper for Some Fans 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Springer to publish Cellular Oncology 2Health News:FDA Panel Recommends Testing of Electroshock Devices 2Health News:FDA Panel Recommends Testing of Electroshock Devices 3Health News:FDA Panel Recommends Testing of Electroshock Devices 4
(Date:9/19/2014)... R.I. , Sept. 19, 2014 Larry ... CVS ), will speak before the National Press ... will discuss the company,s recent move to stop selling tobacco ... shape the future of health. "Dramatic changes in ... health care providers and government," Merlo has said. "CVS Health ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... Surgeons at Self Regional Healthcare,s South Carolina Spine Center ... variety of spinal conditions in its new advanced surgical ... Already recognized by leading health care ratings organization ... continues its commitment to advanced spinal care by becoming ...
... announced today the company has reached another major milestone ... management team roster. DiFUSION Technologies is ... commercialization of its proprietary CleanFUZE ™ anti-microbial technology ... line of Posterior Interbody products. "In ...
Cached Medicine Technology:Self Regional Healthcare Becomes First in the Southeast to Treat Spine Patients Using Advanced Integrated Operating Room Technology From Brainlab 2DiFUSION Technologies Adds Accomplished Senior Management Team 2DiFUSION Technologies Adds Accomplished Senior Management Team 3DiFUSION Technologies Adds Accomplished Senior Management Team 4DiFUSION Technologies Adds Accomplished Senior Management Team 5
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: